Urokinase, which has the function of breaking down specific proteins, is an enzyme substance secreted by the kidneys into urine. It can also be isolated from healthy human urine or obtained from human kidney tissue culture. Urokinase can directly act on the endogenous fibrinolytic system, catalyzing the cleavage of plasminogen into plasmin, which can degrade fibrin clots, as well as fibrinogen, coagulation factor V, and coagulation factor VIII in the bloodstream, thereby exerting thrombolytic effects. ‌

Urokinase is widely used in the treatment of various thrombotic diseases, such as acute myocardial infarction, pulmonary embolism, acute cerebral thrombosis, cerebral embolism, peripheral arterial or venous thrombosis, etc., due to its thrombolytic effect. In addition, urokinase has also been studied for use in fields such as anti-cancer and anti-inflammatory.

Overview of Market Development

Thanks to the advancement of medical technology and the expansion of application fields, the global market size of urokinase is growing year by year. According to our research data, the estimated global urokinase market size in 2024 is $520 million, an increase of 5.78% compared to 2023. It is expected that the market will continue to steadily expand in the coming years. By 2029, the global urokinase market size is expected to increase to $673 million. The CAGR for 2024-2029 is estimated to be 5.29%.

Segmented Market Analysis

From the perspective of product types, urokinase can be divided into two types based on their morphological structure: urokinase freeze-dried powder and urokinase injection. Among them, urokinase freeze-dried powder dominates the market, and its market share is expected to reach 80.09% in 2024.

From the perspective of end-users, urokinase is mainly used in hospitals and clinics. Among them, hospitals dominate the downstream application market, with an expected application share of 78.07% by 2024.

Source: www.globalmarketmonitor.com

Market Analysis of Major Regions/Countries

From a regional perspective, the global urokinase market is concentrated in three major regions: North America, Europe, and Asia Pacific. Among them, the Asia Pacific region is the largest revenue market, with its urokinase market revenue accounting for nearly 70% of the global total market revenue. From a national perspective, China is the largest revenue generating country. Data shows that the estimated revenue of the urokinase market in China in 2024 is $218.68 million, and the market share is expected to reach 42.05%.

Regions/Countries	Market Revenue (Million USD)	Market Share
North America	85.12	16.37%
Europe	60.10	11.56%
China	218.68	42.05%
Japan	30.67	5.90%
India	108.46	20.86%
South America	8.55	1.64%
Middle East & Africa	8.42	1.62%